Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Opportunity and Forecasts to 2020
DUBLIN, Sept. 2, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bq2t2g/world) has announced the addition of the "World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020" report to their offering.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
KEY MARKET BENEFITS:
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global CRPC (metastatic and non-metastatic) market - The CRPC market scenario is comprehensively analysed in accordance to the key regions - In-depth analysis of CRPC (chemotherapy and post-chemo) settings is implemented in the report - The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014-2020 - Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used therapy drugs and evolving role of immunotherapies and radiopharmaceuticals - A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation - Owing to an emerging pipeline in the market, pipeline analysis studies have also been taken into account to better understand the market potential and opportunities - Competitive intelligence highlights the business practices followed by leading market players across geographies
KEY MARKET SEGMENTS:
The Global CRPC market segmentation is illustrated below:
Global CRPC Market By Therapy Type
- Chemotherapy
- - Cytotoxic Agents
- Hormonal Therapy
- - Anti-Androgens
- Immunotherapy
- - Vaccines
- - Radiotherapy
- - Radio-Pharmaceuticals
- Global CRPC Market By Drug Delivery Method
- - Oral Therapy
- - Injectable Therapy
Companies Mentioned
- Astellas Pharma Inc - Bayer - Dendreon Corporation - Johnson & Johnson - Sanofi
For more information visit http://www.researchandmarkets.com/research/bq2t2g/world
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article